Sernova Corp.

TSX:SVA.TO

Biotechnology

Healthcare
$0.14 -5.88%

-$0.01 today

Market cap
$50.98M
Beta
0.66
P/E (TTM)
-4.7
EPS (TTM)
-$0.03
52W Low $0.12High $0.21

Volume 0.55M

Average 0.12M

SVA.TO Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Sernova Corp.TSX: SVA.TO

Accounts Receivables · Q2 FY2026 · quarter ended Apr 2026

Accounts receivables turns positive

Q2 FY2026 accounts receivables was CA$8.75K, compared with -CA$59.69K a year earlier. Trailing-twelve-month accounts receivables was CA$316.14K.

Context

  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near CA$8.75K or moves back toward the trailing-twelve-month quarterly average of CA$79.04K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
CA$8.75K+396.2% QoQ
Last fiscal yearOct 2025
CA$175.47K-68.8% YoY
LTMApr 2026
CA$316.14K-43.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+114.7%——
1 year-68.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

CAD · from the cash flow

Latest · FY2025
175.47K CAD
Year-over-year change
-68.8%

Accounts Receivables vs competitors

How SVA.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.0% is the highest of 2, against a peer median of -1972.1%.
SVA.TO Competitors
Accounts Receivables for SVA.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SVA.TOSernova Corp.LTM Apr 2026CA$316.14K CAD-43.0%——
BCT.TOBriaCell Therapeutics Corp.LTM Apr 2026$224.82K USD-1972.1%——
Peer median (excluding SVA.TO) —-1972.1%——

Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Net Income(6.97M)(24.42M)(39M)(32.19M)(15.74M)
Depreciation & Amortization267.2K440K445.55K540.28K342.59K
Deferred Income Tax0000(70K)
Stock-Based Compensation218.4K7.45M3.9M1.75M2.3M
Change in Working Capital517.56K2.95M4.99M11.16M1.74M
Accounts Receivables(89.8K)(195.04K)229.7K561.85K175.47K
Inventory00000
Accounts Payables00000
Other Working Capital607.35K3.14M4.76M10.6M1.56M
Other Non-Cash Items(881.36K)(838.57K)(676.34K)(150.48K)523.74K
Operating Cash Flow(6.84M)(14.42M)(30.34M)(18.9M)(10.91M)
Capital Expenditures(17.23K)(329K)(99.26K)0(3)
Acquisitions (Net)046M0024.96K
Purchases of Investments0(59M)(18.05M)00
Sales of Investments013M52.97M11.08M0
Other Investing Activities(211.55K)(46.01M)(35.3K)35.3K0
Investing Cash Flow(228.78K)(46.34M)34.78M11.12M24.96K
Debt Repayment(28K)(168.56K)(171.93K)(169.23K)4.94M
Common Stock Issued21.13M20.28M04.96M248.64K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.9M16.55M675.39K277.17K(47.93K)
Financing Cash Flow31M36.66M503.46K5.07M5.14M
Effect of Forex Changes00000
Net Change in Cash23.92M(24.1M)4.95M(2.71M)(5.75M)
Free Cash Flow(6.86M)(14.75M)(30.44M)(18.9M)(10.91M)

Sernova Corp.

TSX:SVA.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.